SUMMARY Eight children with symptoms of HIV infection were treated for 12-26 months (median 14 months) with infusions of intravenous immunoglobulin (200 mg/kg) every three weeks. Significant improvement was noted in all children in terms of weight gain, number of infectious episodes, and days spent in hospital. This resulted in a 49% saving in cost on treatment compared with costs accrued previously during inpatient admissions. Immunoglobulin concentrations, which were raised at the start of treatment were not altered, and T4 counts continued to decline slowly. HIV core antigen was detected in four children before treatment, but all became core antigen negative after treatment was commenced, this effect being sustained in three.
HIV intection in infants and children is associated with high morbidity and mortality,' and present therapeutic options are limited to treatment for specific infections,2 and to zidovudine, which has many documented side effects and unknown long term sequelae.3 As in adults, these infants may present with opportunistic infections and features suggestive of deficiencies of cellular immunity, with reversed T4/T8 ratios.4 5 In addition, however, children commonly present with recurrent bacterial infections,' 6 and defective humoral immunity has been shown. 7 Although serum concentrations of IgG, IgA, and IgM are typically raised,8 panhypogammaglobulinaemia has been described.9"ll Even in the presence of hypergammaglobulinaemia, which is attributed to polyclonal B cell activation,1' patients behave as though they were hypogammaglobulinaemic. Hence passive immunisation in the form of intravenous immunoglobulin has been reported to be of benefit.3'14 The aim of this study, therefore, was to make a fuller evaluation of the clinical effect of at least 12 months' treatment, to document any changes in laboratory indices of viral activity, and to assess the financial implications of committing children to maintenance treatment with intravenous immunoglobulin.
Patients and methods
Eight patients with clinical and laboratory evidence of HIV infection were identified, five of whom have been described in a preliminary report. The procedure and laboratory methods adopted at each visit were as previously described. '7 The financial implications were calculated on the basis that the cost of intravenous immunoglobulin for a 15 
Results
The total number of days spent in hospital for all eight children in the 12 months before treatment After 12 months on treatment subjective improve-(except for case 1 in whom only nine months from ment in general well being was reported in all eight birth had elapsed) was 220 (range 0-60), compared patients. Case 3 showed an initial dramatic improve-with 56 (range 0-20) in the first 12 months on ment in his encephalopathy, as previously des-intravenous immunoglobulin (p<O 001). Assuming cribed,19 but later deteriorated to become severely an unchanged rate of infection, the difference handicapped before finally succumbing to a between actual and expected number of days of pneumonic illness 17 months into treatment. The hospitalisation would be 181-6; this would result in a other seven children remain well enough to attend saving on inpatient costs of £24 905 compared with normal school (n=2) or nursery (n=5) regularly. treatment costs of £12 800. Thus the net saving in Table 2 summaries clinical findings before and after costs of £1513/patient/year, or 49%, even without treatment. The number of infections sufficiently taking into consideration the travelling costs and severe to require hospital review was significantly time lost to the family in attending hospital. reduced on treatment, as was recurrent diarrhoea.
Symptomatic thrombocytopenia, seen in three Improvement in weight gain was seen in the cohort patients before treatment showed no immediate as a whole (p<0-01); the most dramatic change was improvement on this dose of intravenous immunoseen in those children in whom failure to thrive had globulin, and a further child developed purpura been a presenting feature. while on treatment. Hypergammaglobulinaemia, A/F).25 A controlled trial will be necessary if we are to consider treatment in asymptomatic children. This is liable to be problematic, however, because at present there is still no reliable diagnostic test of HIV infection in young children. As the problem of HIV infection in children grows over the next few years, routine intravenous immunoglobulin treatment has major implications in budgeting of hospital inpatient and day care facilities. We have shown the cost benefit of treatment-at least in the short and medium term. In is unlikely, however, that intravenous immunoglobulin will delay progression indefinitely, and further advances in immunotherapy, such as the introduction of specific anti-HIV neutralising antibody in combination with intravenous immunoglobulin and anti-retroviral treatment, will be required if we are to improve the ultimate prognosis for HIV infected children.
